Design, Synthesis, Molecular Docking of Novel Quinazolinone-azole Derivatives as Anticancer A gents

Document Type : Original Article

Authors

1 Department of Medicinal Chemistry, School of Pharmacy, Shiraz University of Medical Sceinces, Shiraz, Iran.

2 Pharmaceutical Sciences Research Center, Shiraz University of Medical Sciences, Shiraz, Iran.

10.30476/tips.2025.105887.1285

Abstract

Cancer encompasses a diverse group of diseases characterized by uncontrolled cell division, leading to immune system impairment and the potential to metastasize to other regions of the body. Globally, cancer represents a significant threat to public health, ranking as the second most prevalent cause of death following cardiovascular diseases. Quinazoline and azole derivatives are important classes of compounds in medicinal chemistry with a wide variety of biological activities. Here, five quinazoline-azole hybrids were designed and synthesized as cytotoxic agents. The chemical structures of new compounds were confirmed using spectroscopic methods. Molecular docking studies were done on epidermal growth factor receptor (EGFR) as a potential target for quinazoline and azole derivatives. The binding energies and interactions of these ligands toward the active site of EGFR were analyzed in comparison with erlotinib. Interestingly, all compounds showed lower binding energies than erlotinib. In silico physicochemical parameters and ADME profiling calculations were also performed.

Highlights

Soghra Khabnadideh (Google Scholar)

Zahra Rezaei (Google Scholar)

Keywords

References

1.    Shaikh SKJ, Kamble RR, Somagond SM, Devarajegowda HC, Dixit SR, Joshi SD. Tetrazolylmethyl quinolines: Design, docking studies, synthesis, anticancer and antifungal analyses. Eur J Med Chem. 2017 Mar 10;128:258-273. doi: 10.1016/j.ejmech.2017.01.043. Epub 2017 Feb 1. PMID: 28192709.
2.    Altıntop MD, Atlı Ö, Ilgın S, Demirel R, Özdemir A, Kaplancıklı ZA. Synthesis and biological evaluation of new naphthalene substituted thiosemicarbazone derivatives as potent antifungal and anticancer agents. Eur J Med Chem. 2016 Jan 27;108:406-414. doi: 10.1016/j.ejmech.2015.11.041. Epub 2015 Nov 30. PMID: 26706351.
3.    Grishko VV, Tolmacheva IA, Nebogatikov VO, Galaiko NV, Nazarov AV, Dmitriev MV, Ivshina IB. Preparation of novel ring-A fused azole derivatives of betulin and evaluation of their cytotoxicity. Eur J Med Chem. 2017 Jan 5;125:629-639. doi: 10.1016/j.ejmech.2016.09.065. Epub 2016 Sep 21. PMID: 27721148.
4.    Ram VJ, Farhanullah, Tripathi BK, Srivastava AK. Synthesis and antihyperglycemic activity of suitably functionalized 3H-quinazolin-4-ones. Bioorg Med Chem. 2003 May 29;11(11):2439-44. doi: 10.1016/s0968-0896(03)00142-1. PMID: 12735990.
5.    Abbas SE, Awadallah FM, Ibrahin NA, Said EG, Kamel GM. New quinazolinone-pyrimidine hybrids: synthesis, anti-inflammatory, and ulcerogenicity studies. Eur J Med Chem. 2012 Jul;53:141-9. doi: 10.1016/j.ejmech.2012.03.050. Epub 2012 Apr 9. PMID: 22551678.
6.    Iemura R, Hori M, Saito T, Ohtaka H. Bioisosteric transformation of H1-antihistaminic benzimidazole derivatives. Chem Pharm Bull (Tokyo). 1989 Oct;37(10):2723-6. doi: 10.1248/cpb.37.2723. PMID: 2575462.
7.    Amin KM, Kamel MM, Anwar MM, Khedr M, Syam YM. Synthesis, biological evaluation and molecular docking of novel series of spiro [(2H,3H) quinazoline-2,1'- cyclohexan]-4(1H)- one derivatives as anti-inflammatory and analgesic agents. Eur J Med Chem. 2010 Jun;45(6):2117-31. doi: 10.1016/j.ejmech.2009.12.078. Epub 2010 Jan 21. PMID: 20137837.
8.    Grover G, Kini SG. Synthesis and evaluation of new quinazolone derivatives of nalidixic acid as potential antibacterial and antifungal agents. Eur J Med Chem. 2006 Feb;41(2):256-62. doi: 10.1016/j.ejmech.2005.09.002. Epub 2005 Nov 2. PMID: 16260068.
9.    Liu JF, Wilson CJ, Ye P, Sprague K, Sargent K, Si Y, et al. Privileged structure-based quinazolinone natural product-templated libraries: identification of novel tubulin polymerization inhibitors. Bioorg Med Chem Lett. 2006 Feb;16(3):686-90. doi: 10.1016/j.bmcl.2005.10.022. Epub 2005 Oct 27. PMID: 16257201.
10.    Dinakaran M, Selvam P, DeClercq E, Sridhar SK. Synthesis, antiviral and cytotoxic activity of 6-bromo-2,3-disubstituted-4(3H)-quinazolinones. Biol Pharm Bull. 2003 Sep;26(9):1278-82. doi: 10.1248/bpb.26.1278. PMID: 12951471.
11.    Al-Blewi F, Shaikh SA, Naqvi A, Aljohani F, Aouad MR, Ihmaid S, et al. Design and Synthesis of Novel Imidazole Derivatives Possessing Triazole Pharmacophore with Potent Anticancer Activity, and In Silico ADMET with GSK-3β Molecular Docking Investigations. Int J Mol Sci. 2021 Jan 25;22(3):1162. doi: 10.3390/ijms22031162. PMID: 33503871; PMCID: PMC7866082.
12.    Alam MM. 1,2,3-Triazole hybrids as anticancer agents: A review. Arch Pharm (Weinheim). 2022 Jan;355(1):e2100158. doi: 10.1002/ardp.202100158. Epub 2021 Sep 24. PMID: 34559414.
13.    Sharma P, LaRosa C, Antwi J, Govindarajan R, Werbovetz KA. Imidazoles as Potential Anticancer Agents: An Update on Recent Studies. Molecules. 2021 Jul 11;26(14):4213. doi: 10.3390/molecules26144213. PMID: 34299488; PMCID: PMC8307698.
14.    Kumar N, Goel N. Recent development of imidazole derivatives as potential anticancer agents. Phys Sci Rev. 2023;8(10):2903-41. doi: 10.1515/psr-2021-0041
15.    Das R, Mehta DK, Dhanawat M. Bestowal of Quinazoline Scaffold in Anticancer Drug Discovery. Anticancer Agents Med Chem. 2021;21(11):1350-1368. doi: 10.2174/1871520620666200627205321. PMID: 32593282.
16.    Șandor A, Ionuț I, Marc G, Oniga I, Eniu D, Oniga O. Structure-Activity Relationship Studies Based on Quinazoline Derivatives as EGFR Kinase Inhibitors (2017-Present). Pharmaceuticals (Basel). 2023 Apr 3;16(4):534. doi: 10.3390/ph16040534. PMID: 37111291; PMCID: PMC10141396.
17.    Biswas T, Mittal RK, Sharma V, Kanupriya, Mishra I. Nitrogen-fused Heterocycles: Empowering Anticancer Drug Discovery. Med Chem. 2024;20(4):369-384. doi: 10.2174/0115734064278334231211054053. PMID: 38192143.
18.    Rehmani HS, Issaeva N. EGFR in head and neck squamous cell carcinoma: exploring possibilities of novel drug combinations. Ann Transl Med. 2020 Jul;8(13):813. doi: 10.21037/atm.2020.04.07. PMID: 32793658; PMCID: PMC7396252.
19.    Seshacharyulu P, Ponnusamy MP, Haridas D, Jain M, Ganti AK, Batra SK. Targeting the EGFR signaling pathway in cancer therapy. Expert Opin Ther Targets. 2012 Jan;16(1):15-31. doi: 10.1517/14728222.2011.648617. Epub 2012 Jan 12. PMID: 22239438; PMCID: PMC3291787.
20.    Shaban N, Kamashev D, Emelianova A, Buzdin A. Targeted Inhibitors of EGFR: Structure, Biology, Biomarkers, and Clinical Applications. Cells. 2023 Dec 25;13(1):47. doi: 10.3390/cells13010047. PMID: 38201251; PMCID: PMC10778338.
21.    Jabir NR, Firoz CK, Bhushan A, Tabrez S, Kamal MA. The Use of Azoles Containing Natural Products in Cancer Prevention and Treatment: An Overview. Anticancer Agents Med Chem. 2018;18(1):6-14. doi: 10.2174/1871520616666160520112839. PMID: 27198985.
22.    Liang Z, Xu H, Tian Y, Guo M, Su X, Guo C. Design, Synthesis and Antifungal Activity of Novel Benzofuran-Triazole Hybrids. Molecules. 2016 Jun 7;21(6):732. doi: 10.3390/molecules21060732. PMID: 27338311; PMCID: PMC6274255.
23.    Wu J, Ni T, Chai X, Wang T, Wang H, Chen J, et al. Molecular docking, design, synthesis and antifungal activity study of novel triazole derivatives. Eur J Med Chem. 2018 Jan 1;143:1840-1846. doi: 10.1016/j.ejmech.2017.10.081. Epub 2017 Nov 11. PMID: 29133044.
24.    Blay JY, von Mehren M. Nilotinib: a novel, selective tyrosine kinase inhibitor. Semin Oncol. 2011 Apr;38 Suppl 1(0 1):S3-9. doi: 10.1053/j.seminoncol.2011.01.016. Erratum in: Semin Oncol. 2011 Jun;38(3):467. PMID: 21419934; PMCID: PMC4004101.
25.    Rix U, Hantschel O, Dürnberger G, Remsing Rix LL, Planyavsky M, Fernbach NV, et al. Chemical proteomic profiles of the BCR-ABL inhibitors imatinib, nilotinib, and dasatinib reveal novel kinase and nonkinase targets. Blood. 2007 Dec 1;110(12):4055-63. doi: 10.1182/blood-2007-07-102061. Epub 2007 Aug 24. PMID: 17720881.
26.    Morales-Vilchis MG, Flores-Sánchez P, Escalante J. Identification, synthesis and structure assignment of two impurities of Erlotinib, a drug used for the treatment of some types of cancer. 
J Mex Chem Soc. 2019;63(1):43-9.
27.    El-Sherief HAM, Youssif BGM, Abbas Bukhari SN, Abdelazeem AH, Abdel-Aziz M, Abdel-Rahman HM. Synthesis, anticancer activity and molecular modeling studies of 1,2,4-triazole derivatives as EGFR inhibitors. Eur J Med Chem. 2018 Aug 5;156:774-789. doi: 10.1016/j.ejmech.2018.07.024. Epub 2018 Jul 10. PMID: 30055463.
28.    Tokala R, Bale S, Janrao IP, Vennela A, Kumar NP, Senwar KR, Godugu C, Shankaraiah N. Synthesis of 1,2,4-triazole-linked urea/thiourea conjugates as cytotoxic and apoptosis inducing agents. Bioorg Med Chem Lett. 2018 Jun 1;28(10):1919-1924. doi: 10.1016/j.bmcl.2018.03.074. Epub 2018 Mar 28. PMID: 29657100.
29.    Nagender P, Naresh Kumar R, Malla Reddy G, Krishna Swaroop D, Poornachandra Y, Ganesh Kumar C, et al. Synthesis of novel hydrazone and azole functionalized pyrazolo[3,4-b]pyridine derivatives as promising anticancer agents. Bioorg Med Chem Lett. 2016 Sep 15;26(18):4427-4432. doi: 10.1016/j.bmcl.2016.08.006. Epub 2016 Aug 4. PMID: 27528432.
30.    Pham Thi T, Le Nhat TG, Ngo Hanh T, Luc Quang T, Pham The C, Dang Thi TA, et al, Nguyen TH, Hoang Thi P, Van Nguyen T. Synthesis and cytotoxic evaluation of novel indenoisoquinoline-substituted triazole hybrids. Bioorg Med Chem Lett. 2016 Aug 1;26(15):3652-7. doi: 10.1016/j.bmcl.2016.05.092. Epub 2016 Jun 1. PMID: 27342752.
31.    Aouad MR, Soliman MA, Alharbi MO, Bardaweel SK, Sahu PK, Ali AA, Messali M, Rezki N, Al-Soud YA. Design, Synthesis and Anticancer Screening of Novel Benzothiazole-Piperazine-1,2,3-Triazole Hybrids. Molecules. 2018 Oct 27;23(11):2788. doi: 10.3390/molecules23112788. PMID: 30373247; PMCID: PMC6278665.
32.    van de Waterbeemd H, Gifford E. ADMET in silico modelling: towards prediction paradise? Nat Rev Drug Discov. 2003 Mar;2(3):192-204. doi: 10.1038/nrd1032. PMID: 12612645.
33.    Emami L, Hassani M, Mardaneh P, Zare F, Saeedi M, Emami M, et al. 6-Bromo quinazoline derivatives as cytotoxic agents: design, synthesis, molecular docking and MD simulation. BMC Chem. 2024 Jul 4;18(1):125. doi: 10.1186/s13065-024-01230-2. PMID: 38965630; PMCID: PMC11225515.
Trends in Pharmaceutical Sciences and Technologies
Volume 11, Issue 2
June 2025
Pages 163-172

Files

Share

How to cite

Statistics